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Abstract Ir(I) complexes of the type [(COD)Ir(NHC)(Py)]PF6 have been 
exposed as efficient catalysts in the area of hydrogen isotope exchange. 
More specifically, via an ortho-directed C-H activation process, high levels of 
deuterium incorporation have been achieved using low levels of catalyst 
over a range of functionalised aromatic compounds. Additionally, the 
developed protocol has been extended to include a selected 
pharmacological target, where chemoselective labelling is observed within 
such a multifunctional substrate.  
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Isotopic labelling with heavy hydrogen isotopes (D2 and T2) is 
widely used as a means to monitor the biological fate of a 
potential drug molecule.2 In relation to this, methods that 
deliver hydrogen isotope exchange (HIE) are of appreciable 
importance in accessing such isotopically-labelled species, 
whilst also being central to the provision of analogous 
deuterated compounds for use as internal standards as aligned 
with mass spectrometry,3 for kinetic isotope studies,4 and for 
the alteration of reaction pathways in total synthesis.5 As such, 
direct, flexible, and selective means of introducing hydrogen 
isotopes continues to be the focus of considerable research 
attention. In this regard, studies from our laboratory have 
shown that a range of iridium complexes of the type 
[(COD)Ir(IMes)(PR3)]X are very effective homogeneous 
catalysts which mediate the exchange of hydrogen with 
deuterium (or tritium) via an ortho-directed C-H activation 
process.2c,6 The key to their applicability in this area lies with 
the ability of such complexes to selectively target unactivated 
C-H bonds, whilst simultaneously allowing convenient isotope 
incorporation with the use of, practically convenient, 
deuterium or tritium gas (Scheme 1). Our developing 
methodology in this domain allows exchange with high levels 
of incorporation using low levels of catalyst and encompasses a 
comprehensive range of substrates including ketone, amide, 
nitro, and a spectrum of heterocyclic functionality, and, most 
recently, primary sulfonamides7 and esters,6f which were 
previously less accessible targets. Indeed, the developed series 
of iridium complexes have emerged to become some of the 
most active species now known in this area of labelling 
chemistry. 
 
Scheme 1 Hydrogen isotope exchange process 
In addition to an isotopic exchange process, our 
[(COD)Ir(IMes)(PR3)]X complexes have been shown to perform 
as effective hydrogenation catalysts, delivering reduced 
products under notably mild reaction conditions.8 In relation to 
this, studies by Nolan et al. have divulged that iridium species 
with the alternative specific combination of a bulky N-
heterocyclic carbene (NHC) and a pyridine ligand represent 
appreciably robust complexes that are active within both 
alkene hydrogenation9 and transfer hydrogenation protocols.10 
In view of these findings, and based on the knowledge that 
judicious and careful manipulation of the ligands supporting 
the iridium centre is critical for success within hydrogen 
isotope exchange processes, we turned our attention to the 
application of the general class of Ir(NHC)(py) complexes 
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within our developing HIE procedures. Herein, we report an 
assessment of iridium(I) complexes of the type 
[(COD)Ir(NHC)(py)]PF6 as an additional series of C-H activation 
catalysts in the deuteration of a range of functionalised arene 
substrates.  
Our initial investigations involved the preparation of catalysts 
3a-c9,10 via the modified preparative procedure shown in Table 
1. In this regard, the desired N-heterocyclic carbene was 
reacted with readily accessible [(COD)Ir(py)2]PF6, 2,11 via a 
simple ligand exchange reaction in toluene. Pleasingly, the 
desired complexes were obtained in very good chemical yield 
in every case. Moreover, this procedure allowed the 
preparation of these extremely stable catalyst species on gram 
scale. 
Table 1 Preparation of Ir complexes -c12 
 
 
Entry NHC Catalyst Yield (%) 
1 IMes, R = 2,4,6-trimethylphenyl  88 
2 IiPr, R = iso-propyl  82 
3 SIMes, R = 2,4,6-trimethylphenyl  97 
 
Having successfully prepared complexes 3a-c, we looked to the 
standard HIE protocol developed within our laboratory for the 
labelling of a variety of substrates. As shown in Scheme 2, 
catalysts 3a-c displayed very good levels of efficiency in our 
labelling protocol. Using only 5 mol% catalyst loading, high 
levels of deuterium incorporation at the expected ortho-
positions were achieved for the selected substrates over 16 h. 
Ketones, amides, pyrazole, and imidazole functionalities were 
all viable within this system, with catalyst 3c, derived from 
SIMes, proving the most active in the majority of cases. Notable 
examples include the labelling of benzamide, 4c; despite this 
substrate previously requiring extremely high levels of catalyst 
and delivering variable results,13a,b complexes 3a-c delivered 
consistently high isotope incorporations for this substrate 
within our study. The [(COD)Ir(NHC)(py)]PF6 complex class 
was also able to deliver very good levels of deuteration with 
acetanilide, 4f, facilitating isotope exchange in C-H bonds 
positioned five bonds away from the required coordinating 
functionality i.e. via a 6-membered metallacyclic intermediate 
(6-mmi). This process is believed to be energetically more 
demanding and, as such, often leads to lower levels of 
deuteration.6a,d Moreover, the delivery of deuterium labelled 
heterocyclic derivatives 5g and 5h displays additional 
versatility and illustrates the overall robustness of this 
catalytic system. Whilst we believe that the encumbered nature 
of the iridium centre within this wider catalyst series is key to 
the high levels of activity shown,6 we were conscious that these 
same steric constraints may disfavour the initial coordination 
of larger and more tetrahedral directing functional units such 
as sulfonamides.7 Having stated this, we were able to induce 
high levels of incorporation within compound 5i, albeit by 
moving to a much higher catalyst loading of 50 mol%. 
Similarly, an increased loading of 10 mol% was required to 
more effectively deliver deuterated ester 5j at a level of 94% D 
incorporation under ambient conditions; again, this was a 
pleasing outcome given the well-documented difficulties 
arising with such a weakly binding aromatic ester group.6f,13  
At this point, it is important to reflect on the preparation and 
performance of this [(COD)Ir(NHC)(py)]PF6 complex class and 
their new application as C-H activation catalysts, as compared 
to our existing and more well-established 
[(COD)Ir(IMes)(PR3)]PF6 series. In relation to this, both 
catalyst classes are readily accessible and provide stable and 
readily handled species for use in HIE processes. Indeed, access 
to the NHC/pyridine complexes described here is relatively 
 
Scheme 2 HIE reaction scope.14 Average incorporation into the positions shown over two separate reaction runs; the percentage given refers to the level of D 
incorporation over the total number of positions shown, e.g. 94% for the two possible positions in  indicates 1.88 D incorporation. a Reaction run using 50 mol% 
catalyst. b Reaction run using 10 mol% catalyst. 
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Table 2 HIE time study using catalyst  
 
Entry Product % D after 30 mina % D after 16 ha 
1  96 94 
2  89 94 
3  33 72 
4  90 96 
5  97 >99 
6  75 89 
7  89 92 
8  10 90 
9  30 (65)b 58 (94)b 
a Average incorporation into the positions shown over two separate reaction 
runs; the percentage given refers to the level of D incorporation over the 
total number of positions shown, e.g. 96% for the two possible positions in 
 indicates 1.92 D incorporation. b Reaction run using 10 mol% catalyst. 
 
more direct overall, notwithstanding the requirement for the 
use of a glove box technique at the outset of the preparative 
process.12 With regards to catalyst performance within the 
described HIE processes, in an overall qualitative sense, the 
NHC/pyridine complexes generally compare well with our 
existing NHC/phosphine series, especially when considering, 
for example, substrates such as acetophenone (4a), 
benzophenone (4b), and 2-phenylpyrazole (4g).6a,d 
Additionally, this current set of catalysts delivered good levels 
of isotopically-labelled benzamide (5c) across the series, 
where the [(COD)Ir(IMes)(PR3)]PF6 complexes delivered 
somewhat more variable results with this primary amide 
substrate.6a,d Moreover and as described above, moving to 
slightly increased catalyst loading, 3c was able to 
accommodate ester functionality at ambient temperatures, 
whereas our previous [(COD)Ir(IMes)(PR3)]PF6 systems 
employed moderately elevated temperatures to deliver similar 
levels of incorporation in ester containing compounds at lower 
catalyst loading.6f  
Encouraged by the results obtained to this stage, we looked to 
more fully probe the reaction parameters in an attempt to 
explore the wider capability of the NHC/pyridine catalyst 
series within these HIE processes. As such, varying levels of 
catalyst loading were explored, as well as a study on the 
reaction rate. Despite lower quantities of catalyst being 
utilisable in the hydrogen isotope exchange of acetophenone, 
4a,15 it was recognised that a reliable quantity of 5 mol% of the 
requisite iridium species was optimal over a range of 
substrates. In addition to these experiments, as shown within 
Table 2, we were pleased to realise that our developed 
labelling protocol was indeed more rapid than anticipated. As 
detailed, after only 30 minutes, using 5 mol% of SIMes catalyst 
3c, comparably high levels of incorporation were achieved 
with the majority of substrates tested as part of our studies. In 
contrast, at 30 minutes reaction time the more demanding 
substrates, benzamide 4c, 2-phenylimidazole 4h, and ethyl 
benzoate 4j did not deliver the high levels of incorporation 
obtained over the more prolonged 16 h process.  
In an extension of these studies and to further illustrate the 
capability of catalysts of type 3, we applied the SIMes derived 
complex 3c in the hydrogen isotope exchange of Sanofi-±ǯǡ6 (Scheme 3). The ability 
to label fully functionalised drug scaffolds is central to the 
application of HIE catalysis, especially as aligned to the 
endeavours of pharmaceutical partners. In this instance we 
were pleased to obtain 86% D incorporation using 20 mol% of 
catalyst, albeit over 42 h. Notably, the observed labelling was 
completely selective, with incorporation occurring at the least 
hindered site of the complex drug target and as directed by the 
adjacent amide functionality via a 5-mmi.  
 
Scheme 3 HIE of a pharmaceutical agent, SR 121463. 
In summary, we have revealed the escalated capability of 
complexes of the type [(COD)Ir(NHC)(py)]PF6 within transition 
metal catalysis. Specifically, such complexes have been shown 
to perform within an ortho-directed C-H activation and 
hydrogen isotope exchange process, delivering high levels of 
deuterium incorporation over a series of functionalised 
aromatic substrates. The established system displays notable 
efficacy under mild reaction conditions and over short reaction 
times. From these studies, catalyst 3c has proven to be the 
most versatile and broadly applicable of the series applied, and 
also providing high levels of selective isotopic labelling within 
a fully functional drug target. With HIE now a key procedure in 
the optimisation of the drug discovery process, the results 
presented in this study are of direct value and importance to 
pharmaceuticals partners. Indeed, ongoing studies within our 
laboratory have the goal of discovering catalysts that are 
compatible with increasingly complex organic molecules and 
alternative drug-like substrates, as well as in the establishment 
of  ?. 
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Acetophenone, 4a: 1H NMR (400 MHz, CDCl3Ȍ Ɂ  ?Ǥ ? ? ȋǡ  ?ȌǢ
7.32 (t, 2H, J = 8.0 Hz); 7.41 (t, 1H, J = 8.0 Hz); 7.81 ppm (d, 2H, J 
= 8.0 Hz).    Ɂ  ?Ǥ ? ?Ǥ  Ɂ ?Ǥ ? ?Ǥ 
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